A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures The primary objective is to determine the tolerability of doses up to a maximum of 12 mg per day of E2007 in patients with refractory partial seizures who are taking inducing and noninducing anti-epil...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations To compare the efficacy of 2mg and 4mg of E2007 and placebo on motor function in patients with Parkinson's disease who are on optimised and stabilised therapy and experience end-of-dose 'wearing off' ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude MK-3475-775 : étude de phase 3 randomisée évaluant l’efficacité et la sécurité du lenvatinib en association avec du pembrolizumab par rapport à un traitement standard déterminé par l’investigateur chez des patientes ayant un cancer de l’endomètre avancé. Le cancer de l'endomètre est la 4e cause de cancer chez la femme en France ; on estime à 7 275 le nombre de nouveaux cas en 2012. Après le cancer du sein, c'est le plus fréquent des cancers gynécologi...

• Pays France
• Organes Utérus
• Spécialités Immunothérapie - Vaccinothérapie, Thérapies Ciblées, Chimiothérapie

Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27) To evaluate the therapeutic activity and safety of E7389 at a dose of 1.4mg/m(2) on days 1 and 8 every 3 weeks in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed followi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment The primary objective of this study is to determine whether donepezil HCl confers cognitive benefit in patients with CADASIL who have cognitive impairment.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone Phase Ib: To determine the dose limiting toxicities and maximally tolerated dose and establish the recommended phase 2 (RP2) dose for E7080 incombination with everolimus in subjects with unresectable ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the combination in patients with metastatic colorectal cancer (CRC) who are resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin To determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC resistant to or unsuitable for treatment...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Disease (GERD) To compare efficacy (i.e. healing and symptom relief) of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg after 4-8 weeks of treatment among subjects with erosive GERD (eG...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase 3 trial studying how well lenvatinib works in treating patients with liver cancer who would not benefit from surgery compared against sorafenib. The trial is taking place worldwide, patients and their physician will know if they are receiving lenvatinib or sorafenib The primary objective of the study is to compare overall survival (OS) in subjects treated with lenvatinib versus sorafenib as a first-line treatment in subjects with unresectable heptocellular carcin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism The primary objective of the study is to determine the rate of major bleeing events in cancer patients receiving extended treatment with dalteparin ( more than 6 months and up to 12 months) for preven...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune